{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:13:23Z","timestamp":1794276803042,"version":"4.9.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Construction Fund of Medical Key Disciplines of Hangzhou","award":["2020SJZDXK004"],"award-info":[{"award-number":["2020SJZDXK004"]}]},{"name":"the Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project","award":["2026ZF71"],"award-info":[{"award-number":["2026ZF71"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03538-8","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T14:22:40Z","timestamp":1767018160000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"30","author":[{"given":"Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heran","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"3538_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/dvdy.24242","volume":"244","author":"ARA McDougall","year":"2015","unstructured":"McDougall ARA, Tolcos M, Hooper SB, Cole TJ, Wallace MJ. Trop2: from development to disease. Dev Dyn. 2015;244:99\u2013109.","journal-title":"Dev Dyn"},{"key":"3538_CR2","doi-asserted-by":"publisher","first-page":"84","DOI":"10.18632\/genesandcancer.40","volume":"6","author":"A Shvartsur","year":"2015","unstructured":"Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications. Genes Cancer. 2015;6:84\u2013105.","journal-title":"Genes Cancer"},{"key":"3538_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108296","author":"X Liu","year":"2022","unstructured":"Liu X, Deng J, Yuan Y, Chen W, Sun W, Wang Y, et al. Advances in Trop2-targeted therapy: novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022. https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108296.","journal-title":"Pharmacol Ther"},{"key":"3538_CR4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000521079","volume":"45","author":"C Hube-Magg","year":"2022","unstructured":"Hube-Magg C, Dum D, Simon R, Bady E, Mandelkow T, Lennartz M, et al. Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: a tissue microarray study on 14,766 tumors. Oncol Res Treat. 2022;45:18\u201318.","journal-title":"Oncol Res Treat"},{"key":"3538_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/pin.12911","volume":"70","author":"R Mito","year":"2020","unstructured":"Mito R, Matsubara E, Komohara Y, Shinchi Y, Sato K, Yoshii D, et al. Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation. Pathol Int. 2020;70:287\u201394.","journal-title":"Pathol Int"},{"key":"3538_CR6","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.7150\/jca.57711","volume":"12","author":"X Sun","year":"2021","unstructured":"Sun X, Jia L, Wang T, Zhang Y, Zhao W, Wang X, et al. Trop2 binding IGF2R induces gefitinib resistance in NSCLC by remodeling the tumor microenvironment. J Cancer. 2021;12:5310\u20139.","journal-title":"J Cancer"},{"key":"3538_CR7","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1158\/1538-7445.AM2022-5127","volume":"82","author":"C-Y Liu","year":"2022","unstructured":"Liu C-Y, Chen J-L, Chu P-Y, Huang C-T, Wang W-L, Huang C-C, et al. Significance of Trop-2 in HER2-positive breast cancer. Cancer Res. 2022;82(12 Suppl):Abstract nr 5127.","journal-title":"Cancer Res"},{"key":"3538_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/ijms23010087","volume":"23","author":"R Erber","year":"2022","unstructured":"Erber R, Spoerl S, Mamilos A, Krupar R, Hartmann A, Ruebner M, et al. Impact of spatially heterogeneous Trop-2 EXPRESSION ON PROGNOSIS IN ORAL SQUAMOUS CELL CARCINOMA. Int J Mol Sci. 2022;23:87.\u00a0doi: 10.3390\/ijms23010087.","journal-title":"Int J Mol Sci"},{"key":"3538_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"3538_CR10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421\u201334.","journal-title":"Adv Drug Deliv Rev"},{"key":"3538_CR11","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1001\/jamaoncol.2019.3552","volume":"5","author":"CM Walko","year":"2019","unstructured":"Walko CM, West H. Antibody drug conjugates for cancer treatment. JAMA Oncol. 2019;5:1648\u20131648.","journal-title":"JAMA Oncol"},{"key":"3538_CR12","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s11912-022-01334-9","volume":"24","author":"JA Marks","year":"2022","unstructured":"Marks JA, Wilgucki M, Liu SV, Reuss JE. Antibody-drug conjugates in non-small cell lung cancer: emergence of a novel therapeutic class. Curr Oncol Rep. 2022;24:1829\u201341.","journal-title":"Curr Oncol Rep"},{"key":"3538_CR13","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, Karibe T, Sakurai K, Aida T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329\u201340.","journal-title":"Mol Cancer Ther"},{"key":"3538_CR14","doi-asserted-by":"publisher","first-page":"7294","DOI":"10.3390\/molecules26237294","volume":"26","author":"G Pavone","year":"2021","unstructured":"Pavone G, Motta L, Martorana F, Motta G, Vigneri P. A new kid on the block: sacituzumab govitecan for the treatment of breast cancer and other solid tumors. Molecules. 2021;26:7294.","journal-title":"Molecules"},{"key":"3538_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","volume":"80","author":"YY Syed","year":"2020","unstructured":"Syed YY. Sacituzumab Govitecan: first approval. Drugs. 2020;80:1019\u201325.","journal-title":"Drugs"},{"key":"3538_CR16","first-page":"159","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard A. FDA approves TROP2-targeted antibody-drug conjugate for breast cancer. Nat Rev Drug Discov. 2025;24:159\u2013159.","journal-title":"Nat Rev Drug Discov"},{"key":"3538_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"3538_CR18","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73:712\u20136.","journal-title":"ANZ J Surg"},{"key":"3538_CR19","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. Cochrane bias methods G and cochrane statistical methods G. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928\u2013d5928.","journal-title":"BMJ."},{"issue":"1","key":"3538_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/mps8010013","volume":"8","author":"E Piragine","year":"2025","unstructured":"Piragine E, Trippoli S, Veneziano S, Messori A, Calderone V. The reconstructed individual patient data from Kaplan-Meier (IPDfromKM) method for non-inferiority analyses: a new potential application. Methods Protoc. 2025;8(1):13. https:\/\/doi.org\/10.3390\/mps8010013.","journal-title":"Methods Protoc"},{"key":"3538_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21:111.","journal-title":"BMC Med Res Methodol"},{"key":"3538_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"3538_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2105\/AJPH.2020.305609","volume":"110","author":"M Nasser","year":"2020","unstructured":"Nasser M. Cochrane handbook for systematic reviews of interventions. Am J Public Health. 2020;110:753\u20134.","journal-title":"Am J Public Health"},{"key":"3538_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383\u201394.","journal-title":"J Clin Epidemiol"},{"key":"3538_CR25","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678.","journal-title":"J Clin Oncol"},{"key":"3538_CR26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01909","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2-and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.23.01909.","journal-title":"J Clin Oncol"},{"key":"3538_CR27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8501","author":"D Planchard","year":"2024","unstructured":"Planchard D, Cozic N, Wislez M, Chouaid C, Curcio H, Cousin S, et al. ICARUS-LUNG01: a phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. J Clin Oncol. 2024. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8501.","journal-title":"J Clin Oncol"},{"key":"3538_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01349","author":"J Sands","year":"2025","unstructured":"Sands J, Ahn M-J, Lisberg A, Cho BC, Blumenschein G Jr., Shum E, et al. Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO-24-01349.","journal-title":"J Clin Oncol"},{"key":"3538_CR29","doi-asserted-by":"publisher","first-page":"260-272","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"M-J Ahn","year":"2025","unstructured":"Ahn M-J, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab Deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. 2025;43:260-272.","journal-title":"J Clin Oncol"},{"key":"3538_CR30","doi-asserted-by":"publisher","first-page":"285-296","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im S-A, Pernas S, De Laurentiis M, Wang S, et al. Datopotamab Deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 2025;43:285-296.","journal-title":"J Clin Oncol"},{"key":"3538_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/ijc.10616","volume":"101","author":"G Mangino","year":"2002","unstructured":"Mangino G, Capri MG, Barnaba V, Alberti S. Presentation of native Trop-2 tumor antigens to human cytotoxic T lymphocytes by engineered antigen-presenting cells. Int J Cancer. 2002;101:353\u20139.","journal-title":"Int J Cancer"},{"key":"3538_CR32","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ddr.21870","volume":"82","author":"S Liao","year":"2021","unstructured":"Liao S, Wang B, Zeng R, Bao H, Chen X, Dixit R, et al. Recent advances in trophoblast cell-surface antigen 2 targeted therapy for solid tumors. Drug Dev Res. 2021;82:1096\u2013110.","journal-title":"Drug Dev Res"},{"key":"3538_CR33","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.jtho.2021.01.280","volume":"16","author":"A Spira","year":"2021","unstructured":"Spira A, Lisberg A, Sands J, Greenberg J, Phillips P, Guevara F, et al. Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: updated results of TROPION-PanTumor01 phase 1 study. J Thorac Oncol. 2021;16:S106\u20137.","journal-title":"J Thorac Oncol"},{"key":"3538_CR34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3153","author":"YY Janjigian","year":"2023","unstructured":"Janjigian YY, Oaknin A, Lang JM, Ciombor KK, Ray-Coquard IL, Oza AM, et al. TROPION-PanTumor03: phase 2, multicenter study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients (pts) with advanced\/metastatic solid tumors. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS3153.","journal-title":"J Clin Oncol"},{"key":"3538_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720","author":"RS Heist","year":"2024","unstructured":"Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102720.","journal-title":"Cancer Treat Rev"},{"key":"3538_CR36","first-page":"oyaf031","volume":"30","author":"F Meric-Bernstam","year":"2025","unstructured":"Meric-Bernstam F, Bardia A, Bossi P, Bianchini G, Gatlin F, Lalla RV, et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis. Oncol. 2025;30:oyaf031.\u00a0 doi: 10.1093\/oncolo\/oyaf031.","journal-title":"Oncol"},{"key":"3538_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","author":"CA Powell","year":"2022","unstructured":"Powell CA, Modi S, Iwata H, Takahashi S, Smit EF, Siena S, et al. Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100554.","journal-title":"ESMO Open"},{"key":"3538_CR38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA Janne","year":"2022","unstructured":"Janne PA, Baik C, Su W-C, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74\u201389.","journal-title":"Cancer Discov"},{"key":"3538_CR39","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/cncr.35349","volume":"130","author":"RJ Li","year":"2024","unstructured":"Li RJ, Hua MQ, Li JL, Chen WH, Xu L, Meng H, et al. The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease and\/or pneumonitis: a systematic review and single-arm meta-analysis. Cancer. 2024;130:2968\u201377.","journal-title":"Cancer"},{"key":"3538_CR40","unstructured":"Sacituzumab govitecan (Trodelvy) for metastatic triple-negative breast cancer. Med Lett Drugs Ther. 2021 Feb 8;63(1617):e25-e27. PMID: 33757114."},{"key":"3538_CR41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1200\/JCO.2024.42.4_suppl.603","volume":"42","author":"A Lisberg","year":"2024","unstructured":"Lisberg A, Drakaki A, Meric-Bernstam F, Alhalabi O, Kojima T, Kato M, et al. Datopotamab deruxtecan in locally advanced\/metastatic urothelial cancer: preliminary results from the phase 1 TROPION-PanTumor01 study. J Clin Oncol. 2024;42:603\u2013603.","journal-title":"J Clin Oncol"},{"key":"3538_CR42","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.1016\/j.annonc.2024.08.776","volume":"35","author":"A Oaknin","year":"2024","unstructured":"Oaknin A, Ang JE, Rha SY, Yonemori K, Kristeleit R, Lin CC, et al. Datopotamab deruxtecan (Dato-DXd) in patients with endometrial (EC) or ovarian cancer (OC): results from the phase II TROPION-PanTumor03 study. Ann Oncol. 2024;35:S547\u20138.","journal-title":"Ann Oncol"},{"key":"3538_CR43","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/1535-7163.MCT-17-0749","volume":"17","author":"TN Iwata","year":"2018","unstructured":"Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494\u2013503.","journal-title":"Mol Cancer Ther"},{"key":"3538_CR44","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1172\/JCI126598","volume":"130","author":"K Haratani","year":"2020","unstructured":"Haratani K, Yonesaka K, Takamura S, Maenishi O, Kato R, Takegawa N, et al. U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation. J Clin Invest. 2020;130:374\u201388.","journal-title":"J Clin Invest"},{"key":"3538_CR45","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.jtho.2023.09.043","volume":"18","author":"KP Papadopoulos","year":"2023","unstructured":"Papadopoulos KP, Bruno D, Kitazono S, Murakami S, Gutierrez M, Wakuda K, et al. Datopotamab Deruxtecan (Dato-DXd) plus Durvalumab \u00b1 Carboplatin in Advanced\/mNSCLC: initial results from phase 1b TROPION-Lung04. J Thorac Oncol. 2023;18:S55\u2013S55.","journal-title":"J Thorac Oncol"},{"key":"3538_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241248336","author":"A Bardia","year":"2024","unstructured":"Bardia A, Pusztai L, Albain K, Ciruelos EM, Im S-A, Hershman D, et al. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Ther Adv Med Oncol. 2024. https:\/\/doi.org\/10.1177\/17588359241248336.","journal-title":"Ther Adv Med Oncol"},{"key":"3538_CR47","doi-asserted-by":"crossref","unstructured":"McArthur HL, Tolaney SM, Dent R, Schmid P, Asselah J, Liu Q, et al. TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-na\u00efve early-stage triple negative or HR-low\/HER2- breast cancer. Ther Adv Med Oncol. 2025 Feb 5;17:17588359251316176. doi: 10.1177\/17588359251316176.","DOI":"10.1177\/17588359251316176"},{"key":"3538_CR48","doi-asserted-by":"publisher","first-page":"103282","DOI":"10.1016\/j.esmoop.2024.103282","volume":"9","author":"P Schmid","year":"2024","unstructured":"Schmid P, Oliveira M, O\u2019Shaughnessy J, Cristofanilli M, Graff SL, Im SA, et al. TROPION-Breast05: phase (Ph) III study of datopotamab deruxtecan (Dato-DXd) \u00b1 durvalumab (D) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). ESMO Open. 2024;9(Suppl 4):103282.","journal-title":"ESMO Open"},{"key":"3538_CR49","doi-asserted-by":"publisher","first-page":"P01","DOI":"10.1158\/1538-7445.SABCS23-PO1-19-10","volume":"84","author":"P Schmid","year":"2024","unstructured":"Schmid P, Ma C, Huisden R, Stewart R, Heider K, Vukovic P, et al. Durvalumab + datopotamab deruxtecan in patients with PD-L1 positive advanced\/metastatic triple-negative breast cancer: arm 8 of the phase 1b\/2, open label, platform BEGONIA study. Cancer Res. 2024;84(9 Suppl):Abstract nrPO1-19-10.","journal-title":"Cancer Res"},{"key":"3538_CR50","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1080\/14796694.2024.2409621","volume":"20","author":"I Okamoto","year":"2024","unstructured":"Okamoto I, Kuyama S, Girard N, Lu S, Franke F, Li Z, et al. TROPION-Lung07: phase III study of Dato-DXd plus pembrolizumab \u00b1 platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncol. 2024;20:2927\u201336.","journal-title":"Future Oncol"},{"key":"3538_CR51","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.2217\/fon-2023-0230","volume":"19","author":"BP Levy","year":"2023","unstructured":"Levy BP, Felip E, Reck M, Yang JCH, Cappuzzo F, Yoneshima Y, et al. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Future Oncol. 2023;19:1461\u201372.","journal-title":"Future Oncol"},{"key":"3538_CR52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1332489","author":"X Liu","year":"2023","unstructured":"Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1332489.","journal-title":"Front Immunol"},{"key":"3538_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188902","author":"S Qiu","year":"2023","unstructured":"Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochimica et Biophysica Acta (BBA). 2023. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188902.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"3538_CR54","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","volume":"14","author":"X Liu","year":"2024","unstructured":"Liu X, Ma L, Li J, Sun L, Yang Y, Liu T, et al. Trop2-targeted therapies in solid tumors: advances and future directions. Theranostics. 2024;14:3674\u201392.","journal-title":"Theranostics"},{"key":"3538_CR55","doi-asserted-by":"publisher","first-page":"S212-S213","DOI":"10.1016\/S1556-0864(25)00549-0","volume":"20","author":"YL Wu","year":"2025","unstructured":"Wu YL, Xiao Z, Li J, Long J, Li W, Cheng Y, et al. Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced\/metastatic non-small cell lung cancer (a\/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02. J Thorac Oncol. 2025;20:S212-S213.","journal-title":"J Thorac Oncol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03538-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03538-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03538-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T15:05:11Z","timestamp":1767020711000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40001-025-03538-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3538"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03538-8","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"3 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1265"}}